CD274 and neoplasm: Furthermore, the NSABP FR-2 (18) and PANDORA trials (19) explored the use of durvalumab (a PD-L1 inhibitor) as consolidation therapy following nCRT, with the PANDORA trial reporting a pCR rate of 32.7% and notable benefits in tumor downstaging and sphincter preservation.